Skip to main content

Table 1 Phase III trials of EGFR TKIs versus chemotherapy as first line therapy in NSCLC EGFR mutated patients

From: The epidermal growth factor receptor (EGRF) in lung cancer

Study TKI Chemotherapy Population Response rate (EGFR TKI vs chemotherapy) % Disease control rate (EGFR TKI vs chemo) % Progression free survival (EGFR TKI vs chemo) m Overall survival (EGFR TKI vs chemo) m
IPASS (Sub-study) 1 Gefitinib Carbo/Pac Asian (E/SE) 71.2 47.3 91.7 87.6 9 6 21.6 21.9
     p 0.001   p 0.001 NS
EURTAC 2 Erlotinib Cis OR Carbo + Doc OR Gem Caucasian 58 15 79 66 9.4 5.2 NR NR
     p < 0.001 p <0.001 p < 0.0001   
OPTIMAL 3 Erlotinib Carbo/Gem Asian (China) 83 36 96 82 13.1 4.6 NR NR
     p 0.00001 p <0.0001 p < 0.0001  
WJTOG 3405 4 Gefitinib Cis/Doc Asian (Japan) 62.1 32.2 93.1 78 9.2 6.3 30.9 NR
     p < 0.0001 p 0.02 p < 0.0001 p 0.211
NEJSG 002 5 Gefitinib Carbo/Pac Asian (Japan) 73.7 30 86 79 10.8 5.4 30.5 23.6
     p < 0.001   p < 0.001 p 0.353
LUX-Lung 3 6 Afatinib Cis/Pem Majority Asian 56.1 22.6 NR NR 11.1 6.9 31.6 28.2
     p < 0.0001    p 0.0004 p 0.109
LUX-Lung 6 7 Afatinib Cis/Gem Asian (E/SE) 67 23 93 76 11 5.6 23.6 23.5
     p < 0.0001 p < 0.0001 p 0.001 p0.175
  1. 1Mok, et al. N Engl J Med 2009 [36]; 2; 2Rosell, et al. Lancet Oncol 2012 [40]; 3Zhou, et al. Lancet Oncol 2011 [39]; 4Mitsudomi, et al. Lancet Oncol 2010 [37]; 5Maemondo, et al. N Engl J Med 2010 [38]; 6Sequist, et al. J Clin Oncol 2013 [43]; 7Wu, et al. ASCO 2013 [44].